Real-life Study of the Efficacy of Management of Migraine Patients After Failure of 2 Prophylactic Treatments
NCT ID: NCT05947123
Last Updated: 2024-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
127 participants
OBSERVATIONAL
2023-06-01
2024-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Data describing their care will be extracted from computerized patient records.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fremanezumab for the Prevention of Menstrually-related Migraine Attacks
NCT06659120
The Evolution and Management of Migraine Recurrence Beyond 24 Hours
NCT00754611
Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
NCT03238781
A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)
NCT01513291
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
NCT01617941
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Patient health care observational follow up after 2 prophylactic tratments
Real-life, observational, single-center cohort study to describe the efficacy of prophylactic treatment in patients after failure of at least 2 prophylactic treatments. Patients included in the study will be followed up in consultations or day hospitals according to their usual care, and will be asked to complete the MIDAS, HIT-6, PGIC, HAD and WPAI questionnaires at each visit. Data describing their care will be extracted from computerized patient records.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Monthly number of attacks ≥ 8 for at least 3 months
* Indication for prophylactic treatment
* For eptinezumab: resistance to at least 2 conventional disease-modifying therapies
* Agrees to use data for research purposes
Exclusion Criteria
* Need for analgesics for a cause other than migraine
* Difficulty in understanding French language or cognitive impairment that compromises completion of self-questionnaires.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Régional Metz-Thionville
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xavier DUCROCQ, MD
Role: PRINCIPAL_INVESTIGATOR
CHR Metz Thionville Hopital de Mercy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHR Metz-Thionville/Hopital de Mercy
Metz, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-07Obs-CHRMT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.